M. [Célestin] Jonnart, sénateur du Pas-de-Calais [dans la cour d'honneur du Sénat] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57616

M. [Alexandre] Ribot, sénateur du Pas-de-Calais [payant un taxi devant l'entrée du Sénat] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57618

Les adresses ne s'usent... que lorsque l'on ne s'en sert pas !

Le processus de sortie est complexe, il s'inscrit dans une visée dischronique (un projet qui dépasse le temps de séjour au CTJ) et synchronique (l'état du patient doit être compatible avec l'adresse que nous lui proposons). Ce processus est amorcé par l'adresseur, dès la demande d'admission qui implicitement doit avoir une adresse de sortie en toile de fond. Les aléas de la prise en charge ne doivent pas faire disparaître les points de mire (les adresses de sortie) qui doivent être sollicitées, entretenues, dans une collaboration qui laisse entendre un« service après vente» possible. Dès l'entrée, la question de la sortie est donc pensée par et avec le patient. Les soins s'inscrivent dans un processus de continuité et de réhabilitation, à travers un travail pluridisciplinaire intimement lié à l'environnement extérieur du patient. La sortie ne met pas toujours un point final à une prise en charge, le suivi ambulatoire est un moyen efficace et progressif pour y parvenir.

Cancer du sein: inhibiteurs de l'aromatase en situation adjuvante, un peu, beaucoup ou pas du tout [Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]

Several large randomized trials showed that tamoxifen alone is no more the standard adjuvant hormonal therapy for menopausal patients. Aromatase inhibitors, given upfront or sequentially after tamoxifen, confirmed their efficacy by improving disease free survival, risk of distant metastasis and overall survival in some situations or subgroups of patients. These drugs are usually well tolerated, but they clearly increase bone mineral density loss as well as the risk of fractures and their long term safety on the cardio-vascular system needs to be followed. Thus, even if the role of the aromatase inhibitors is now evident in the adjuvant therapy of postmenopausal women the benefice/risk ratio should be carefully evaluated for each patient.

Abaisser la pression arterielle: urgent ou pas urgent? [How urgent is it to decrease high blood pressure?]

Severe hypertension represents a frequent problem for the general practitioner. One has to decide if the blood pressure needs to be decreased immediately (hypertensive emergency), or if the blood pressure maybe progressively decreased in a few hours and normalized in a few days (hypertensive crisis). Thus it is crucial to identify on the basis of the clinical history and a careful physical examination, the patients for whom the arterial blood pressure elevation represents an acute danger for organ damage or a vital threat in the absence of immediate blood pressure control. In the case of hypertensive crisis, oral medication is usually sufficient (slow release or GITS nifedipine, nitroglycerin, labetalol, captopril). The hypertensive emergency sometimes requires an oral medication before the admission to the emergency room, then followed by intravenous drug administration (sodium nitroprussiate, nitroglycerin, labetalol).

Patient with syncope and LQTS carrying a mutation in the PAS domain of the hERG1 channel.

We report the case of a woman with syncope and persistently prolonged QTc interval. Screening of congenital long QT syndrome (LQTS) genes revealed that she was a heterozygous carrier of a novel KCNH2 mutation, c.G238C. Electrophysiological and biochemical characterizations unveiled the pathogenicity of this new mutation, displaying a 2-fold reduction in protein expression and current density due to a maturation/trafficking-deficient mechanism. The patient's phenotype can be fully explained by this observation. This study illustrates the importance of performing genetic analyses and mutation characterization when there is a suspicion of congenital LQTS. Identifying mutations in the PAS domain or other domains of the hERG1 channel and understanding their effect may provide more focused and mutation-specific risk assessment in this population.